Biofrontera, Inc. (BFRI) Price-to-Projected Revenue Ratio

Corporate emblem and logo of Biofrontera Inc (BFRI)

Biofrontera Inc. generates revenue from the sale of dermatological systems and medications for the treatment of acne and precancer in the US. The projected P/S value on the GURU.Markets chart serves as a confidence indicator, with the current mark equal to 0.30. Strict medical protocols ensure stable income, while high clinic loyalty is maintained through the supply of Ameluz lamps under rigorous FDA supervision.

Biofrontera, Inc. - BFRI Future Price to Revenue (period 07/04/2022 - 11/13/2026)

BFRI (biofrontera-us.com): analytical breakdowns and indicator data

- current price and projected stock value:
Stock Price Biofrontera|BFRI - Analyst Median Target
- market capitalization details:
Market Value Biofrontera|BFRI - Total Enterprise Value
- book value of equity indicators:
Book Value per Share Biofrontera|BFRI - Net Asset Value|Market Value to Book Value Ratio biofrontera-us.com|BFRI - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Biofrontera Inc.|BFRI - Long-Term Liabilities to Capital|Short-Term Debt to Equity Biofrontera|BFRI - Company Aggregate Debt|Debt to Book Value Biofrontera|BFRI - Amount of Long-Term Liabilities|Company Short-Term Debts Biofrontera|Quick Liquidity biofrontera-us.com
- financial results and valuation multiples details:
BFRI - Final Profit|Projected Future Earnings Biofrontera Inc.|BFRI - P/E Multiple|Projected Price to Earnings Biofrontera|BFRI - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Biofrontera|BFRI - Operating income before deduction of amortization|Earnings per share for the last twelve months Biofrontera|BFRI - Earnings per share for the last 12 months|Quarterly EPS earnings growth biofrontera-us.com|BFRI - Net earnings per share growth this year|Expected earnings per share growth for next year Biofrontera Inc.
- sales volume and revenue information:
BFRI - Company Gross Revenue|Projected Sales Volume Biofrontera|BFRI - Price-to-Revenue Ratio|Forward P/S Multiple Biofrontera
Fundamental company valuation:Biofrontera Inc (BFRI)
Original product of Biofrontera

For Biofrontera Inc. (BFRI), whose revenue depends critically on a single therapy method and patent protection, the projected P/S ratio serves as an indicator of market expectations regarding future revenue streams. The ratio of current market capitalization to forecasted sales allows investors to assess the asset's degree of overvaluation, considering the risks of generic expansion and a potential reduction in government medical subsidies.

Competing companies

Forward P/S Multiple KRYS (Krystal Biotech)|Market Cap to Expected Sales Ratio Apogee Therapeutics Inc (APGE)|ARQT - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Vericel Inc.|ORKA: Forward P/S Multiple|Future Price to Revenue SMTI (Sanara MedTech)|Price-to-Projected Revenue Ratio DBV Tech|SLSN: Forward Price to Sales|Price-to-Projected Revenue Ratio Journey Medical (DERM)|FBRX - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Empro Group Inc EMPG|SLGL: Market Cap to Projected Revenue|AXIL: Forward Price-to-Revenue Multiple|Medicus Pharma Ltd - Price to Expected Revenue Ratio|VRCA: Forward P/S Multiple|Market Cap to Future Revenue Ratio Hoth Therapeutics (HOTH)|Price-to-Projected Revenue Ratio VYNE Therapeutics, Inc.|SNOA: Forward Price to Sales|Forward P/S Multiple QNRX|Forward P/S Multiple Azitra Inc (AZTR)|Dermata - Forward Price-to-Revenue Multiple|Forward Price to Sales ELAB|Revance Therapeutics - Forward P/S Multiple